rVSV-ZEBOV vaccine

EDCTP and CEPI Funding Moves IAVI's Lassa fever Vaccine Candidate Into Advanced Clinical Development

Retrieved on: 
Tuesday, June 15, 2021
AIDS, Health, Other Health, General Health, Clinical trials, Research, Science, Medical specialties, Clinical medicine, Medicine, Ebola, Breakthrough therapy, Vaccines, West African Ebola virus epidemic, Lassa fever, Ebola vaccine, rVSV-ZEBOV vaccine, Vaccine, Lassa, Lassa Fever, EDCTP, CEPI, IAVI, LASSA FEVER, EDCTP, CEPI, IAVI

Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.

Key Points: 
  • Despite this disease burden, which is believed to be significantly underestimated, no vaccine for Lassa fever is currently available.
  • The joint award supports an international collaboration, called Lassa Fever Vaccine Efficacy and Prevention for West Africa (LEAP4WA), to conduct a Phase IIb clinical trial of IAVIs Lassa fever vaccine candidate among adults and children in Liberia, Nigeria, and Sierra Leone.
  • LEAP4WA builds on an existing partnership with CEPI that supports IAVI and a global consortium of partners to conduct Phase I and II clinical trials of IAVIs Lassa fever vaccine candidate.
  • We are excited to apply the recombinant VSV technology, used in the previously licensed Ebola vaccine called ERVEBO, for the development of a much-needed Lassa fever vaccine.

FDA Approves First Treatment for Ebola Virus

Retrieved on: 
Wednesday, October 14, 2020
Medical specialties, Medicine, Infectious diseases, Biological weapons, Tropical diseases, Zoonoses, West African Ebola virus epidemic, Ebola, Zaire ebolavirus, rVSV-ZEBOV vaccine, Ebola vaccine, Science diplomacy and pandemics

Zaire ebolavirus, commonly known as Ebola virus, is one of four Ebolavirus species that can cause a potentially fatal human disease.

Key Points: 
  • Zaire ebolavirus, commonly known as Ebola virus, is one of four Ebolavirus species that can cause a potentially fatal human disease.
  • Individuals who provide care for people with Ebola virus, including health care workers who do not use correct infection control precautions, are at the highest risk for infection.
  • Inmazeb received an Orphan Drug designation for the treatment of Ebola virus infection.
  • The FDA approved Ervebo, the first vaccine for the prevention of Ebola virus disease, in December 2019, with support from a study conducted in Guinea during the 2014-2016 Ebola outbreak.

Seed of hope: COVID-19 vaccine trials begin

Retrieved on: 
Thursday, April 2, 2020
Medicine, Health, Ebola, Clinical medicine, Vaccines, West African Ebola virus epidemic, Biological weapons, Tropical diseases, Ebola vaccine, Vaccine, Ebola virus disease, rVSV-ZEBOV vaccine

Once proves effective after three phases of clinical trials, the vaccine is expected to be available for the public in as little as six months' time.

Key Points: 
  • Once proves effective after three phases of clinical trials, the vaccine is expected to be available for the public in as little as six months' time.
  • Having previously traveled to Sierra Leone during the Ebola outbreak, she developed China's first homegrown vaccine for the virus, making China the third country to put an Ebola vaccine into clinical trials.
  • After two months of hard work, they developed the recombinant novel coronavirus vaccine, using the same technology as was used for the Ebola vaccine.
  • The COVID-19 vaccine is a seed of hope for humanity, and one which is showing positive signs.

AHF Lauds WHO’s Belated Pre-Qualification of the Ebola Vaccine

Retrieved on: 
Thursday, November 14, 2019
FDA, Other Consumer, Health, Philanthropy, Healthcare reform, Pharmaceutical, Other Government, Infectious diseases, Foundation, Public policy, Government, Consumer, Medicine, Ebola, Medical specialties, Clinical medicine, Vaccines, West African Ebola virus epidemic, Biological weapons, Tropical diseases, rVSV-ZEBOV vaccine, Ebola vaccine, Vaccine, Ebola virus disease

AHF has been calling for an approved vaccine for more than a yeareven before the current outbreak in the DRC (Democratic Republic of the Congo) began last August.

Key Points: 
  • AHF has been calling for an approved vaccine for more than a yeareven before the current outbreak in the DRC (Democratic Republic of the Congo) began last August.
  • Were glad the WHO has finally pre-qualified itunfortunately, this is bittersweet because it has taken entirely too long given the devastation that Ebola brings and the clear evidence of the vaccines efficacy, said AHF President Michael Weinstein.
  • The success of the first trial for the Merck Ebola vaccine, rVSV-ZEBOV, was first reported in the Lancet in July 2015 .
  • The WHO pre-qualification comes on the heels of vaccines approval by the European Commission , which makes it the first officially approved Ebola vaccine in the world.

NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)

Retrieved on: 
Tuesday, November 12, 2019
Medicine, Health, Medical specialties, Ebola, Vaccines, West African Ebola virus epidemic, Ebola vaccine, Vaccine, Ebola virus disease, Food and Drug Administration, rVSV-ZEBOV vaccine

AMES, Iowa, Nov. 12, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that Monday, November 11th, the European Commission (EC) granted a conditional marketing authorization to ERVEBO, investigational V920 Ebola Zaire vaccine (rVSVG-ZEBOV-GP) , as confirmed by our partner, Merck (NYSE:MRK), known as MSD outside the US and Canada.

Key Points: 
  • AMES, Iowa, Nov. 12, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that Monday, November 11th, the European Commission (EC) granted a conditional marketing authorization to ERVEBO, investigational V920 Ebola Zaire vaccine (rVSVG-ZEBOV-GP) , as confirmed by our partner, Merck (NYSE:MRK), known as MSD outside the US and Canada.
  • With this approval, the EC will grant a centralized marketing authorization for the vaccine with unified labeling that is valid in 31 European countries.
  • As NewLink has previously stated, the FDAs approval of this Ebola vaccine would trigger the issuance of a priority review voucher owned by Merck and in which NewLink Genetics has a substantial economic interest.
  • NewLink Genetics is a clinical-stage biopharmaceutical company that has historically focused on developing novel immunotherapeutic products for the treatment of patients with cancer.

AHF to WHO: Approve the Ebola Vaccine Now!

Retrieved on: 
Thursday, April 18, 2019
Health, Infectious diseases, Public policy, Government, Other Government, Other Policy Issues, Medicine, Medical specialties, Infectious diseases, Ebola, Vaccines, West African Ebola virus epidemic, Biological weapons, Tropical diseases, rVSV-ZEBOV vaccine, Ebola vaccine, Ebola virus disease, Ebola virus

The study estimates that efficacy of the Merck Ebola vaccine rVSV-ZEBOV-GP is at 97.5% and showed the ability to reduce the overall mortality rate even among individuals who developed the disease.

Key Points: 
  • The study estimates that efficacy of the Merck Ebola vaccine rVSV-ZEBOV-GP is at 97.5% and showed the ability to reduce the overall mortality rate even among individuals who developed the disease.
  • As of April 15, there have been 1,273 total cases and 821 deathsthe worst fatality rate (62%) of any Ebola outbreak in history.
  • If there was ever a time to accelerate the licensing of a proven vaccine and declare an emergencythis is it, said Michael Weinstein, AHF President.
  • AHF calls on WHO to do everything in its power to stamp out Ebola in the Congo, including expediting the approval of the rVSV-ZEBOV-GP vaccine and pushing for the declaration of a PHEIC.